Media Articles Related to Opana (Oxymorphone)
Angola denies report that Dos Santos treated for cancer in Spain
Source: Yahoo Health News [2013.11.29]
Angola on Friday denied a report by Portuguese state TV that the oil-producing African state's long-serving President Jose Eduardo dos Santos was undergoing cancer treatment in Spain. "I don't have anything to say, because it is not ...
Untreated cancer pain a 'scandal of global proportions,' survey shows
Source: Health News from Medical News Today [2013.11.28]
A ground-breaking international collaborative survey, published in Annals of Oncology, shows that more than half of the world's population live in countries where regulations that aim to stem drug misuse leave cancer patients without access to opioid medicines for managing cancer pain.The results from the Global Opioid Policy Initiative (GOPI)  project show that more than 4 billion people live in countries where regulations leave cancer patients suffering excruciating pain.
Chest Pain in Women Looks a Lot Like Men's
Source: Medscape Nurses Headlines [2013.11.26]
A new review of almost 2500 emergency-department admissions suggests that the presentation of chest pain between men and women is not as different as is commonly thought.
9 Things Chronic Pain Specialists Want Hospitalists to Know
Source: Medscape Pharmacists Headlines [2013.11.26]
Read these useful pearls regarding opioid use and abuse, as well as tips regarding general pain management, from an expert team of chronic pain specialists.
Findings not supportive of using women-specific chest pain symptoms in early diagnosis of heart attack
Source: Cardiovascular / Cardiology News From Medical News Today [2013.11.26]
Using chest pain characteristics (CPCs) specific to women in the early diagnosis of acute myocardial infarction (AMI, heart attack) in the emergency department does not seem to be supported by the findings of a study published by JAMA Internal Medicine, a JAMA Network publication.
Published Studies Related to Opana (Oxymorphone)
Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users. [2011.05]
OBJECTIVE: To compare the subjective effects of oxymorphone extended release (OM-ER) versus oxycodone controlled release (OC-CR)... CONCLUSIONS: At equianalgesic doses, single oral intact OM-ER produced lower positive, negative, and balance subjective effects than OC-CR, indicating that analgesic potency may not necessarily be reflected in subjective/objective effects.
Reduced cognitive and psychomotor impairment with extended-release oxymorphone versus controlled-release oxycodone. [2010.11]
BACKGROUND: Opioids provide effective pain control, yet have risks including adverse events (AEs) (e.g., constipation, nausea/vomiting, sedation) and cognitive/psychomotor effects. OBJECTIVE: To compare cognitive and psychomotor effects of oxymorphone extended release (OM-ER) versus oxycodone controlled release (OC-CR)... CONCLUSION: Single oral intact low and high doses of OM-ER produced less cognitive and psychomotor impairment plus less sedation than equianalgesic OC-CR in this exploratory study. ClinicalTrials.gov registration NCT00955110.
Long-term tolerability and effectiveness of oxymorphone extended release in patients with cancer. [2010.05]
OBJECTIVE: To evaluate the long-term safety, tolerability, and effectiveness of oxymorphone extended release (ER) in patients with cancer-related pain... CONCLUSIONS: In these patients with pain related to cancer, oxymorphone ER was generally well tolerated and provided stable long-term pain control.
The pain quality response profile of oxymorphone extended release in the treatment of low back pain. [2009.02]
OBJECTIVE: In controlled trials of analgesics, the primary outcome variable is most often a measure of global pain intensity. However, because pain is associated with a variety of pain sensations, the effects of analgesic treatments on different sensations could go undetected if specific pain qualities are not assessed...
Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use. [2009.02]
OBJECTIVE: This study assessed the potential effects of age, sex, and prior opioid use on the response to oxymorphone extended release (ER) in patients with moderate to severe chronic low back pain... CONCLUSION: In the enriched population of patients who successfully titrated to oxymorphone ER, oxymorphone ER was effective and generally well tolerated, independent of patients' age, sex, or previous opioid use.
Clinical Trials Related to Opana (Oxymorphone)
Effect of Extended-Release Oxymorphone Taking With or Without Food on Cognitive Functioning [Recruiting]
The purpose of the study is to determine whether extended-release oxymorphone hydrochloride
taken orally with a high-fat meal, generating an approximately 50% higher Cmax, impacts
cognitive functioning, using Cambridge Neuropsychological Test Automated Battery (CANTAB)
tests, to a greater extent than when taking under conditions of fasting.
Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects [Recruiting]
A Pilot Study of Ultra Rapid Opioid Rotation and Titration of Oxymorphone [Recruiting]
This project will explore the safety and feasibility of performing a successful intravenous
patient controlled analgesia (IV PCA) Oxymorphone titration and conversion to oral ER
Oxymorphone (extended release or OPANA ER) in the outpatient setting.
Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects [Recruiting]
Patients will convert from current opioid to Oxymorphone ER and undergo titration. During
the Titration Period, subjects will receive daily oxymorphone Extended Release tablets(s)
every 12 hours. Dosing adjustments will be based on the review of the subject's pain
scores. Oxymorphone IR 5 mg will be provided to be used as supplemental "breakthrough" pain
medication (as needed). Titration Period will end when the fixed dose of study medication
is tolerated and the subject achieves adequate analgesia. Subjects will then proceed to the
open-label 3-month maintenance period on the fixed dose of study medication established
during the Titration Period.
Open-Label Safety and Tolerability Study of Oxymorphone for Acute Postoperative Pain in Pediatric Subjects. [Recruiting]
When post-operative parenteral analgesia is discontinued, oral dosing with study medication
may begin once the subject has developed a moderate level of pain as defined by a 100 mm VAS
(pain intensity score greater than or equal to 40).
Reports of Suspected Opana (Oxymorphone) Side Effects
Drug Abuse (22),
Drug Ineffective (20),
Weight Decreased (15),
Drug Dependence (15),
Respiratory Depression (12),
Intentional Drug Misuse (11),
Pain (10), more >>